Phaseline

Targets › GAD2

GAD2 (Glutamate decarboxylase 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2028.

Catalyzes the production of GABA. (UniProt, Q05329)

Open in Phaseline: the race on GAD2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Diamyd MedicalDiamyd
GAD65 antigen therapy
GAD2Phase 2Diabetes Mellitus, Type 1Mar 2028

Conditions

Diabetes Mellitus, Type 1 (1)

Modalities

small molecule (1)

Companies

Diamyd Medical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.